QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 morgan-stanley-reiterates-overweight-on-viking-therapeutics-maintains-105-price-target

Morgan Stanley analyst Michael Ulz reiterates Viking Therapeutics (NASDAQ:VKTX) with a Overweight and maintains $105 price t...

 viking-therapeutics-stock-could-soar-45-ahead-of-key-weight-loss-drug-readout-jpmorgan

JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics with an Overweight rating and a December 2025 price ta...

 jp-morgan-initiates-coverage-on-viking-therapeutics-with-overweight-rating-announces-price-target-of-80

JP Morgan analyst Hardik Parikh initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a Overweight rating and announc...

 fake-ozempic-targets-weight-loss-market-forged-batches-an-international-concern

Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation...

Core News & Articles

- Reuters 

 jim-cramer-hold-on-to-builders-firstsource-heres-the-problem-with-viking-therapeutics

Jim Cramer discusses Serve Robotics, Builders FirstSource, Vertex Pharmaceuticals and Viking Therapeutics on CNBC.

 viasat--ast-spacemobile-are-among-top-6-mid-cap-stocks-that-shined-the-brightest-last-week-july-21-july-27-are-the-others-in-your-portfolio

Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72%

 novo-nordisk-shares-decline-amid-competitive-pressure

Novo Nordisk A/S Common Stock (NYSE: NVO) experienced a notable decline on Thursday. This movement follows a significant announ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION